Table 4.
The baseline characteristics according to the ICPI group in the ICIs cohort.
| Low-risk ICPI | Moderately high-risk ICPI | P value | |
|---|---|---|---|
| n = 101 | n = 42 | ||
| Sex | 0.314 | ||
| Male | 19 (18.8) | 5 (11.9) | |
|
| |||
| Age (year) | 0.923 | ||
| ≥65 | 40 (39.6) | 17 (40.5) | |
|
| |||
| Smoking status | 0.031 | ||
| Nonsmoker | 21 (20.8) | 16 (38.1) | |
| Smoker | 80 (79.2) | 26 (61.9) | |
|
| |||
| Histology | 0.960 | ||
| Adenocarcinoma | 52 (51.5) | 21 (50.0) | |
| Squamous | 43 (42.6) | 18 (42.9) | |
| NSCLC-others | 6 (5.9) | 3 (7.1) | |
|
| |||
| KRAS alteration status | 0.496 | ||
| KRAS wild-type | 43 (42.6) | 22 (52.4) | |
| KRAS-mutant | 5 (5.0) | 1 (2.4) | |
| NA | 53 (52.5) | 19 (45.2) | |
|
| |||
| PD-L1 status | 0.622 | ||
| Negative | 6 (5.9) | 2 (4.8) | |
| Positive | 15 (14.9) | 9 (21.4) | |
| NA | 80 (79.2) | 31 (73.8) | |
|
| |||
| PS (ECOG) | 0.085 | ||
| 0-1 | 101 (100) | 40 (95.2) | |
| ≥2 | 0 (0) | 2 (4.8) | |
|
| |||
| Stage | 0.090 | ||
| I-II | 7 (6.9) | 0 (0) | |
| IIIA | 8 (7.9) | 1 (2.4) | |
| IIIB–IV | 86 (85.1) | 41 (97.8) | |
|
| |||
| Metastatic sites number | <0.001 | ||
| <2 | 50 (49.5) | 7 (16.7) | |
| ≥2 | 51 (50.5) | 35 (83.3) | |
|
| |||
| Metastatic sites | |||
| Live | 9 (8.9) | 9 (21.4) | 0.04 |
| Bone | 16 (15.8) | 18 (42.9) | 0.001 |
| Brain | 14 (13.9) | 5 (11.9) | 0.754 |
| WBC (×109/L) | 6.44 (5.22–7.75) | 8.11 (6.09–10.13) | <0.001 |
| ANC (×109/L) | 4.04 (2.81–5.10) | 6.02 (4.69–8.00) | <0.001 |
| ALC (×109/L) | 1.60 (1.13–1.95) | 1.01 (0.81–1.54) | <0.001 |
| MON (×109/L) | 0.54 (0.39–.071) | 0.61 (0.41–0.75) | 0.879 |
| RDW (%) | 13.4 (13.0–14.6) | 14.6 (13.6–14.9) | 0.150 |
| PLT (×109/L) | 231 (163–289) | 212 (180–309) | 0.929 |
| ALB (g/L) | 42.93 ± 3.61 | 36.49 ± 4.26 | <0.001 |
| PLR | 139.0 (110.1–198.4) | 218.5 (144.2–284.5) | <0.001 |
| dNLR | 1.93 (1.16–2.28) | 3.62 (2.51–4.31) | <0.001 |
|
| |||
| ICIs drug | 0.028 | ||
| Sintilimab | 18 (90) | 2 (10) | |
| Nivolumab | 21 (56.8) | 16 (43.2) | |
| Pembrolizumab | 62 (72.1) | 24 (27.9) | |
|
| |||
| ICIs treatment modality | 0.011 | ||
| ICI monotherapy | 26 (56.5) | 20 (43.5) | |
| ICI + chemotherapy | 75 (77.3) | 22 (22.7) | |
| ICI + antiangiogenic | |||
|
| |||
| ICIs line | 0.168 | ||
| 1 | 36 (35.6) | 10 (23.8) | |
| ≥2 | 65 (64.4) | 32 (76.2) | |
|
| |||
| Previous treatments | |||
| Chemotherapy | 61 (60.4) | 28 (66.7) | 0.481 |
| Radiotherapy | 11 (10.9) | 12 (28.6) | 0.009 |
| EGFR-TKI | 8 (7.9) | 4 (9.5) | 0.753 |
| Antiangiogenic | 16 (15.8) | 9 (21.4) | 0.423 |
| Surgery | 9 (8.9) | 4 (9.5) | 0.156 |
|
| |||
| Disease response | 0.103 | ||
| CR | 2 (2.0) | 0 (0) | |
| PR | 44 (43.6) | 16 (38.1) | |
| SD | 42 (41.6) | 13 (31.0) | |
| PD | 13 (12.9) | 13 (21.0) | |
|
| |||
| Response rates | |||
| ORR (%) | 45.5 | 38.1 | 0.714 |
| DCR (%) | 87.1 | 69 | 0.031 |